Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Keratitis | 14 | 2022 | 107 | 4.190 |
Why?
|
| Corneal Stroma | 12 | 2022 | 80 | 3.180 |
Why?
|
| Eye Infections, Fungal | 7 | 2021 | 73 | 2.350 |
Why?
|
| Corneal Diseases | 5 | 2021 | 96 | 1.790 |
Why?
|
| Corneal Ulcer | 8 | 2017 | 54 | 1.420 |
Why?
|
| Herpes Zoster Vaccine | 2 | 2021 | 11 | 1.310 |
Why?
|
| Microsporidiosis | 3 | 2021 | 6 | 1.150 |
Why?
|
| Fluoroquinolones | 3 | 2018 | 97 | 1.140 |
Why?
|
| Keratoplasty, Penetrating | 7 | 2021 | 51 | 1.110 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2019 | 14 | 1.100 |
Why?
|
| Antifungal Agents | 2 | 2021 | 311 | 1.080 |
Why?
|
| Herpes Zoster Ophthalmicus | 2 | 2018 | 12 | 1.030 |
Why?
|
| Polymers | 2 | 2019 | 110 | 1.030 |
Why?
|
| Herpesvirus 3, Human | 2 | 2018 | 30 | 1.020 |
Why?
|
| Acanthamoeba Keratitis | 3 | 2021 | 16 | 0.870 |
Why?
|
| Antiprotozoal Agents | 4 | 2021 | 42 | 0.850 |
Why?
|
| Slit Lamp Microscopy | 1 | 2021 | 6 | 0.740 |
Why?
|
| Eye Infections, Viral | 1 | 2022 | 28 | 0.740 |
Why?
|
| Phosphorylcholine | 1 | 2021 | 25 | 0.730 |
Why?
|
| Herpes Zoster | 2 | 2021 | 26 | 0.720 |
Why?
|
| Cornea | 10 | 2015 | 597 | 0.690 |
Why?
|
| Anti-Bacterial Agents | 9 | 2018 | 2556 | 0.680 |
Why?
|
| Herpesvirus 4, Human | 3 | 2022 | 675 | 0.680 |
Why?
|
| Eye Infections, Bacterial | 7 | 2015 | 86 | 0.610 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 293 | 0.610 |
Why?
|
| Gentamicins | 3 | 2018 | 87 | 0.580 |
Why?
|
| Vaccines, Subunit | 1 | 2018 | 70 | 0.580 |
Why?
|
| Voriconazole | 1 | 2018 | 34 | 0.570 |
Why?
|
| Virus Activation | 1 | 2018 | 85 | 0.570 |
Why?
|
| Disinfectants | 2 | 2015 | 28 | 0.500 |
Why?
|
| Contact Lens Solutions | 1 | 2015 | 5 | 0.490 |
Why?
|
| Lubricant Eye Drops | 1 | 2015 | 10 | 0.490 |
Why?
|
| Mycoses | 3 | 2012 | 117 | 0.440 |
Why?
|
| Microsporidia | 3 | 2021 | 3 | 0.440 |
Why?
|
| Ophthalmic Solutions | 3 | 2019 | 90 | 0.410 |
Why?
|
| Corneal Opacity | 2 | 2010 | 22 | 0.400 |
Why?
|
| Aza Compounds | 1 | 2012 | 15 | 0.390 |
Why?
|
| Quinolines | 1 | 2012 | 122 | 0.360 |
Why?
|
| Visual Acuity | 8 | 2021 | 707 | 0.340 |
Why?
|
| Contact Lenses | 4 | 2011 | 42 | 0.330 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 271 | 0.320 |
Why?
|
| Paraproteinemias | 1 | 2010 | 22 | 0.320 |
Why?
|
| Immunoglobulin G | 3 | 2010 | 803 | 0.310 |
Why?
|
| Glucocorticoids | 3 | 2022 | 386 | 0.290 |
Why?
|
| Drug Therapy, Combination | 5 | 2018 | 1162 | 0.280 |
Why?
|
| Staphylococcus aureus | 3 | 2007 | 479 | 0.280 |
Why?
|
| Mydriatics | 1 | 2007 | 10 | 0.270 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2007 | 8 | 0.270 |
Why?
|
| Keratoconjunctivitis | 2 | 2007 | 19 | 0.270 |
Why?
|
| Middle Aged | 23 | 2021 | 28888 | 0.260 |
Why?
|
| Humans | 45 | 2022 | 132334 | 0.260 |
Why?
|
| Keratitis, Herpetic | 2 | 2004 | 22 | 0.260 |
Why?
|
| Male | 32 | 2021 | 65052 | 0.260 |
Why?
|
| Eye Infections, Parasitic | 2 | 2003 | 8 | 0.260 |
Why?
|
| Aged | 19 | 2021 | 21379 | 0.250 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 7111 | 0.220 |
Why?
|
| Adult | 19 | 2022 | 31618 | 0.220 |
Why?
|
| Burkholderia | 1 | 2003 | 6 | 0.210 |
Why?
|
| Burkholderia Infections | 1 | 2003 | 8 | 0.210 |
Why?
|
| Enterococcus | 1 | 2003 | 31 | 0.210 |
Why?
|
| Eye Diseases | 3 | 1992 | 117 | 0.210 |
Why?
|
| Young Adult | 4 | 2021 | 9945 | 0.200 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 5405 | 0.200 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 1205 | 0.200 |
Why?
|
| Conjunctival Diseases | 3 | 1997 | 26 | 0.200 |
Why?
|
| Staphylococcal Infections | 2 | 2007 | 569 | 0.190 |
Why?
|
| Graft Rejection | 3 | 2021 | 560 | 0.190 |
Why?
|
| Female | 26 | 2022 | 70786 | 0.190 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2003 | 97 | 0.190 |
Why?
|
| Vision Disorders | 3 | 2021 | 217 | 0.180 |
Why?
|
| Loteprednol Etabonate | 1 | 2021 | 5 | 0.180 |
Why?
|
| Microscopy, Confocal | 2 | 2021 | 369 | 0.180 |
Why?
|
| Drug Substitution | 1 | 2021 | 20 | 0.180 |
Why?
|
| Anti-Allergic Agents | 1 | 2021 | 27 | 0.180 |
Why?
|
| Contact Lenses, Hydrophilic | 2 | 2015 | 21 | 0.180 |
Why?
|
| Paecilomyces | 2 | 2012 | 4 | 0.180 |
Why?
|
| Infectious Mononucleosis | 3 | 1990 | 15 | 0.160 |
Why?
|
| Amikacin | 2 | 2003 | 26 | 0.160 |
Why?
|
| Biopsy | 2 | 2021 | 1288 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 392 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 338 | 0.150 |
Why?
|
| Prednisolone | 1 | 2018 | 73 | 0.150 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 2010 | 29 | 0.150 |
Why?
|
| Corneal Transplantation | 4 | 1987 | 45 | 0.150 |
Why?
|
| Streptococcal Infections | 3 | 1993 | 248 | 0.140 |
Why?
|
| Conjunctivitis | 2 | 2015 | 20 | 0.140 |
Why?
|
| Adolescent | 10 | 2021 | 20552 | 0.130 |
Why?
|
| Moyamoya Disease | 1 | 1997 | 42 | 0.130 |
Why?
|
| Retrospective Studies | 9 | 2021 | 17363 | 0.130 |
Why?
|
| Incidence | 3 | 2021 | 3361 | 0.130 |
Why?
|
| Hypersensitivity, Delayed | 2 | 1986 | 33 | 0.120 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2015 | 5 | 0.120 |
Why?
|
| Nocardia | 1 | 2015 | 8 | 0.120 |
Why?
|
| Silicone Elastomers | 1 | 2015 | 22 | 0.120 |
Why?
|
| Nocardia Infections | 1 | 2015 | 13 | 0.120 |
Why?
|
| Anterior Eye Segment | 2 | 2011 | 25 | 0.110 |
Why?
|
| Maxillary Sinus | 1 | 1994 | 12 | 0.110 |
Why?
|
| Enophthalmos | 1 | 1994 | 9 | 0.110 |
Why?
|
| Bone Resorption | 1 | 1994 | 52 | 0.110 |
Why?
|
| Endophthalmitis | 2 | 1984 | 68 | 0.100 |
Why?
|
| Mycobacterium chelonae | 1 | 1993 | 4 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1986 | 520 | 0.100 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 187 | 0.100 |
Why?
|
| Aspergillus | 1 | 2012 | 26 | 0.100 |
Why?
|
| Ascomycota | 1 | 2012 | 26 | 0.100 |
Why?
|
| DNA, Viral | 1 | 2014 | 492 | 0.100 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 3 | 1993 | 45 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2018 | 13016 | 0.090 |
Why?
|
| Chlorpromazine | 1 | 1992 | 12 | 0.090 |
Why?
|
| Child | 8 | 2021 | 25823 | 0.090 |
Why?
|
| Candida | 1 | 2012 | 83 | 0.090 |
Why?
|
| Pneumococcal Infections | 1 | 1994 | 277 | 0.090 |
Why?
|
| Scleritis | 1 | 2011 | 10 | 0.090 |
Why?
|
| Streptococcus pneumoniae | 1 | 1994 | 381 | 0.090 |
Why?
|
| Myiasis | 1 | 1991 | 7 | 0.090 |
Why?
|
| Fibronectins | 1 | 1991 | 107 | 0.090 |
Why?
|
| Bacterial Adhesion | 1 | 1991 | 106 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 1556 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1991 | 175 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2009 | 1297 | 0.080 |
Why?
|
| Keratotomy, Radial | 1 | 1989 | 31 | 0.080 |
Why?
|
| Eye Injuries | 2 | 2011 | 42 | 0.080 |
Why?
|
| Leprosy, Lepromatous | 1 | 1989 | 2 | 0.080 |
Why?
|
| Clofazimine | 1 | 1989 | 7 | 0.080 |
Why?
|
| Acanthamoeba | 1 | 1989 | 10 | 0.080 |
Why?
|
| Stents | 1 | 2015 | 873 | 0.080 |
Why?
|
| Cryosurgery | 1 | 1989 | 47 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 2010 | 148 | 0.070 |
Why?
|
| Iris | 1 | 2008 | 44 | 0.070 |
Why?
|
| Cross Infection | 1 | 1991 | 342 | 0.070 |
Why?
|
| United States | 2 | 2021 | 11627 | 0.070 |
Why?
|
| Rupture, Spontaneous | 1 | 2007 | 47 | 0.070 |
Why?
|
| Mycobacterium Infections | 1 | 1987 | 32 | 0.070 |
Why?
|
| Optic Neuritis | 1 | 1987 | 34 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2008 | 195 | 0.070 |
Why?
|
| Rabbits | 4 | 1994 | 688 | 0.070 |
Why?
|
| Syphilis | 1 | 1987 | 98 | 0.060 |
Why?
|
| HIV Seropositivity | 1 | 1987 | 129 | 0.060 |
Why?
|
| Cataract | 1 | 2008 | 169 | 0.060 |
Why?
|
| Tobramycin | 2 | 1992 | 22 | 0.060 |
Why?
|
| Herpesviridae Infections | 1 | 1987 | 146 | 0.060 |
Why?
|
| Cnidaria | 1 | 1985 | 2 | 0.060 |
Why?
|
| Scyphozoa | 1 | 1985 | 2 | 0.060 |
Why?
|
| Transplantation Immunology | 1 | 1985 | 45 | 0.060 |
Why?
|
| Bites and Stings | 1 | 1985 | 27 | 0.060 |
Why?
|
| Animals | 12 | 2009 | 34989 | 0.060 |
Why?
|
| Mucus | 1 | 1985 | 36 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2015 | 825 | 0.060 |
Why?
|
| Corneal Injuries | 1 | 1985 | 35 | 0.060 |
Why?
|
| Tissue Donors | 2 | 2009 | 508 | 0.060 |
Why?
|
| Benzamidines | 3 | 2008 | 10 | 0.060 |
Why?
|
| Microbiological Techniques | 3 | 2011 | 34 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2006 | 203 | 0.050 |
Why?
|
| Administration, Topical | 3 | 2008 | 140 | 0.050 |
Why?
|
| Serologic Tests | 3 | 1990 | 130 | 0.050 |
Why?
|
| Ofloxacin | 1 | 2003 | 31 | 0.050 |
Why?
|
| Levofloxacin | 1 | 2003 | 47 | 0.050 |
Why?
|
| Cyclohexanes | 1 | 2003 | 8 | 0.050 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1985 | 222 | 0.050 |
Why?
|
| Vancomycin | 2 | 2003 | 222 | 0.050 |
Why?
|
| Sesquiterpenes | 1 | 2003 | 26 | 0.050 |
Why?
|
| HIV Seronegativity | 1 | 2003 | 30 | 0.050 |
Why?
|
| Albendazole | 1 | 2003 | 29 | 0.050 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2003 | 79 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 66 | 0.050 |
Why?
|
| Prevalence | 3 | 2011 | 2664 | 0.050 |
Why?
|
| Virus Diseases | 1 | 1984 | 291 | 0.040 |
Why?
|
| Fungi | 2 | 2011 | 76 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 3 | 2009 | 1052 | 0.040 |
Why?
|
| Cataract Extraction | 2 | 2008 | 152 | 0.040 |
Why?
|
| Eyelashes | 1 | 1997 | 3 | 0.040 |
Why?
|
| Hair Diseases | 1 | 1997 | 12 | 0.040 |
Why?
|
| Crystallization | 2 | 2006 | 89 | 0.040 |
Why?
|
| Hawaii | 1 | 1997 | 7 | 0.030 |
Why?
|
| Foreign-Body Reaction | 1 | 1997 | 16 | 0.030 |
Why?
|
| Syndrome | 2 | 1994 | 1171 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 1997 | 118 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 1997 | 197 | 0.030 |
Why?
|
| Major Histocompatibility Complex | 2 | 1986 | 53 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 1992 | 3139 | 0.030 |
Why?
|
| Intubation | 1 | 2015 | 15 | 0.030 |
Why?
|
| Conjunctiva | 2 | 1989 | 186 | 0.030 |
Why?
|
| Dacryocystorhinostomy | 1 | 2015 | 18 | 0.030 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 45 | 0.030 |
Why?
|
| Immunity, Cellular | 2 | 1986 | 204 | 0.030 |
Why?
|
| Paranasal Sinus Diseases | 1 | 1994 | 15 | 0.030 |
Why?
|
| Serotyping | 1 | 1994 | 178 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 1986 | 648 | 0.030 |
Why?
|
| Bone Remodeling | 1 | 1994 | 56 | 0.030 |
Why?
|
| Streptococcus sanguis | 1 | 1993 | 2 | 0.030 |
Why?
|
| Orbit | 1 | 1994 | 84 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1993 | 234 | 0.020 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1993 | 68 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 1991 | 87 | 0.020 |
Why?
|
| Risk Factors | 3 | 2011 | 10910 | 0.020 |
Why?
|
| Diptera | 1 | 1991 | 27 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1229 | 0.020 |
Why?
|
| Epithelium | 1 | 1991 | 354 | 0.020 |
Why?
|
| Larva | 1 | 1991 | 259 | 0.020 |
Why?
|
| Insect Vectors | 1 | 1991 | 113 | 0.020 |
Why?
|
| Fluoresceins | 1 | 1989 | 33 | 0.020 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1989 | 25 | 0.020 |
Why?
|
| Mycobacterium | 1 | 1989 | 30 | 0.020 |
Why?
|
| Lectins | 1 | 1989 | 49 | 0.020 |
Why?
|
| Paromomycin | 1 | 1989 | 4 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 1989 | 48 | 0.020 |
Why?
|
| Neomycin | 1 | 1989 | 36 | 0.020 |
Why?
|
| Natamycin | 1 | 2009 | 3 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 1989 | 73 | 0.020 |
Why?
|
| Lenses, Intraocular | 1 | 1992 | 277 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 258 | 0.020 |
Why?
|
| Amphotericin B | 1 | 2009 | 91 | 0.020 |
Why?
|
| Schizophrenia | 1 | 1992 | 332 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1989 | 341 | 0.020 |
Why?
|
| Trabeculectomy | 1 | 2008 | 15 | 0.020 |
Why?
|
| Biguanides | 1 | 2008 | 13 | 0.020 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 1988 | 8 | 0.020 |
Why?
|
| Chlorhexidine | 1 | 2008 | 47 | 0.020 |
Why?
|
| Vision, Binocular | 1 | 2008 | 28 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 1989 | 265 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1994 | 2169 | 0.020 |
Why?
|
| Atrophy | 1 | 2008 | 253 | 0.020 |
Why?
|
| Adenoviridae Infections | 1 | 1987 | 69 | 0.020 |
Why?
|
| Bacteria | 1 | 2011 | 528 | 0.020 |
Why?
|
| Glaucoma | 1 | 2008 | 79 | 0.020 |
Why?
|
| Infant | 2 | 1997 | 13192 | 0.020 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 1986 | 43 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 1986 | 4767 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1986 | 76 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1989 | 324 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 1986 | 125 | 0.020 |
Why?
|
| Langerhans Cells | 1 | 1985 | 21 | 0.020 |
Why?
|
| Mice | 3 | 2009 | 18571 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1985 | 54 | 0.010 |
Why?
|
| Sensation | 1 | 1985 | 51 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1985 | 133 | 0.010 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 1985 | 43 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1987 | 596 | 0.010 |
Why?
|
| Trifluridine | 1 | 2004 | 9 | 0.010 |
Why?
|
| Acyclovir | 1 | 2004 | 47 | 0.010 |
Why?
|
| Spleen | 1 | 1985 | 275 | 0.010 |
Why?
|
| Blepharitis | 1 | 1984 | 8 | 0.010 |
Why?
|
| Amblyopia | 1 | 2004 | 25 | 0.010 |
Why?
|
| Molluscum Contagiosum | 1 | 1984 | 11 | 0.010 |
Why?
|
| Mumps | 1 | 1984 | 12 | 0.010 |
Why?
|
| Chickenpox | 1 | 1984 | 22 | 0.010 |
Why?
|
| Vidarabine | 1 | 2004 | 80 | 0.010 |
Why?
|
| Herpesvirus 1, Human | 1 | 2004 | 34 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1986 | 234 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1986 | 273 | 0.010 |
Why?
|
| Foreign Bodies | 1 | 1985 | 110 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 1984 | 16 | 0.010 |
Why?
|
| Graft Survival | 1 | 1986 | 475 | 0.010 |
Why?
|
| Dendrites | 1 | 1985 | 204 | 0.010 |
Why?
|
| Adenovirus Infections, Human | 1 | 1984 | 57 | 0.010 |
Why?
|
| Measles | 1 | 1984 | 43 | 0.010 |
Why?
|
| Herpes Simplex | 1 | 1984 | 56 | 0.010 |
Why?
|
| Epitopes | 1 | 1985 | 437 | 0.010 |
Why?
|
| Streptococcus | 1 | 1984 | 63 | 0.010 |
Why?
|
| Eye | 1 | 1985 | 236 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1985 | 388 | 0.010 |
Why?
|
| Skin | 1 | 1986 | 540 | 0.010 |
Why?
|
| Epithelium, Corneal | 1 | 2004 | 171 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 1984 | 225 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 2227 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 1458 | 0.010 |
Why?
|
| Child, Preschool | 3 | 2004 | 14851 | 0.010 |
Why?
|
| Time Factors | 1 | 1989 | 6455 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2004 | 822 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 4695 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 5150 | 0.010 |
Why?
|
| Cefazolin | 1 | 1992 | 20 | 0.010 |
Why?
|
| Solubility | 1 | 1992 | 124 | 0.010 |
Why?
|
| Lens Capsule, Crystalline | 1 | 1992 | 30 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1992 | 97 | 0.010 |
Why?
|
| Vitreous Body | 1 | 1992 | 96 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1992 | 279 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1984 | 8566 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1992 | 273 | 0.010 |
Why?
|
| Fluorescein | 1 | 1989 | 39 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1989 | 161 | 0.000 |
Why?
|
| Ophthalmology | 1 | 1992 | 197 | 0.000 |
Why?
|
| Abscess | 1 | 1989 | 140 | 0.000 |
Why?
|
| Parotid Gland | 1 | 1986 | 21 | 0.000 |
Why?
|
| Salivary Glands | 1 | 1986 | 34 | 0.000 |
Why?
|
| Craniocerebral Trauma | 1 | 1988 | 139 | 0.000 |
Why?
|
| Lacrimal Apparatus | 1 | 1986 | 128 | 0.000 |
Why?
|
| Autoantibodies | 1 | 1986 | 459 | 0.000 |
Why?
|
| Texas | 1 | 1992 | 3628 | 0.000 |
Why?
|
| Internship and Residency | 1 | 1992 | 1252 | 0.000 |
Why?
|
| Prognosis | 1 | 1988 | 5009 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1986 | 6540 | 0.000 |
Why?
|